CoChat
Sign Up
Cited by 698Fungal Infections and StudiesAntifungal resistance and susceptibilityParasitic Infections and Diagnostics

Cryptococcosis

Open access
Maziarz, Eileen K., Perfect, John R.·2016·Infectious Disease Clinics of North America
DOI 10.1016/j.idc.2015.10.006PMC PMC5808417
Open this paper in CoChat — free account

Abstract

Cryptococcosis is an invasive mycosis caused by pathogenic encapsulated yeasts in the genus Cryptococcus. Cryptococcus gained prominence as a pathogen capable of widespread disease outbreaks in vulnerable populations. We have gained insight into the pathobiology of Cryptococcus, including the yeast' s capacity to adapt to environmental pressures, exploit new geographic environments, and cause disease in both immunocompromised and apparently immunocompetent hosts. Inexpensive, point-of-care testing makes diagnosis more feasible than ever. The associated worldwide burden and mortality remains unacceptably high. Novel screening strategies and preemptive therapy offer promise at making a sustained and much needed impact on this sugar-coated opportunistic mycosis.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.idc.2015.10.006

Cites

11 of 11 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • The incidence of MRSA varies by region (ranging from ~2% in Western Europe to 10% in North America) and by patient-related characteristics.

    “The incidence of MRSA varies, however, by region (ranging from ~2% in Western Europe to 10% in North America) and by patient-related characteristics (133, 136, 137).”

    From Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2021. (2021) · cites this paper as [136]

    The Epidemiology and Risk Factors section discusses cryptococcosis, not MRSA. Searches for MRSA and methicillin-resistant Staphylococcus aureus found no passage addressing the claimed regional percentages or patient-related variation in MRSA incidence. No page numbers were supplied for the passages. (LLM, conf=0.78)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 179

  1. [1]Knoke M Schwesinger G One hundred years ago: the history of cryptococcosis in Greifswald. Medical mycology in the nineteenth century Mycoses 1994 37 229 33 7739651
  2. [2]Casadevall A Perfect JR Cryptococcus neoformans Washington, DC ASM Press 1998
  3. [3]Park BJ Wannemuehler KA Marston BJ Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS AIDS 2009 23 525 30 19182676
  4. [4]Kidd SE Hagen F Tscharke RL A rare genotype of Cryptococcus gattii caused the cryptococcosis outbreak on Vancouver Island (British Columbia, Canada) Proc Natl Acad Sci U S A 2004 101 17258 63 15572442 PMC535360
  5. [5]MacDougall L Fyfe M Romney M Risk factors for Cryptococcus gattii infection, British Columbia, Canada Emerg Infect Dis 2011 17 2 193 9 21291588 PMC3204768
  6. [6]Marr K Datta K Pirofski L Cryptococcus gattii Infection in healthy Hosts: A Sentinel for Subclinical Immunodeficiency? Clin Infect Dis 2012 54 1 153 4 22075791
  7. [7]Rosen L Freeman A Yang L Anti-GM-CSF autoantibodies in patients with cryptococcal meningitis J Immunol 2013 190 3959 66 23509356 PMC3675663
  8. [8]Saijo T Chen J Chen S Anti-granulocyte macrophage colony-stimulating factor autoantibodies are a risk factor for central nervous system infection by Cryptococcus gattii in otherwise immunocompetent patients MBio 2014 5 2 e00912 4 24643864 PMC3967522
  9. [9]Mitchell D Sorrell T Allworth A Cryptococcal disease of the CNS in immunocompetent hosts: influence of cryptococcal variety on clinical manifestations and outcome Clin Infect Dis 1995 20 611 6 7756484
  10. [10]Harris J Lockhart S Debess E Cryptococcus gattii in the United States: clinical aspects of infection with an emerging pathogen Clin Infect Dis 2011 53 1188 95 22016503
  11. [11]Chen S Meyer W Sorrell T Cryptococcus gattii infections Clin Microbiol Rev 2014 27 4 980 1024 25278580 PMC4187630
  12. [12]Phillips P Galanis E MacDougall L Longitudinal clinical findings and outcome among patients with Cryptococcus gattii infection in British Columbia Clin Infect Dis 2015 60 9 1368 76 25632012
  13. [13]Hagen F Khayhan K Theelen B Recognition of seven species in the Cryptococcus gatti/Cryptococcus neoformans species complex Fungal Genet Biol 2015 78 16 48 25721988
  14. [14]Chen S Sorrell T Nimmo G Epidemiology and host- and variety-dependent characteristics of infection due to Cryptococcus neoformans in Australia and New Zealand. Australasian Cryptococcal Study Group Clin Infect Dis 2000 31 499 508 10987712
  15. [15]Chen Y Litvintseva A Frazzitta A Comparative analyses of clinical and environmental populations of Cryptococcus neoformans in Botswana Mol Ecol 2015 24 14 3559 71 26053414 PMC4758399
  16. [16]Emmons C Saprophytic sources of Cryptococcus neoformans associated with the pigeon (Columba livia) Am J Hyg 1955 62 3 227 32 13268414
  17. [17]Steenbergen J Shuman H Casadevall A Cryptococcus neoformans interactions with amoebae suggest an explanation for its virulence and intracellular pathogenic strategy in macrophages Proc Natl Acad Sci U S A 2001 98 15245 11742090 PMC65014
  18. [18]Ruiz A Neilson J Bulmer G Control of Cryptococcus neoformans in nature by biotic factors Sabouraudia 1982 20 1 21 9 6801787
  19. [19]Ellis D Pfeiffer T Natural habitat of Cryptococcus neoformans var gattii J Clin Microbiol 1990 28 1642 4 2199524 PMC268004
  20. [20]Hoang L Maguire J Doyle P Cryptococcus neoformans infections at Vancouver Hospital and Health Sciences Centre (1997–2002): epidemiology, microbiology and histopathology J Med Microbiol 2004 53 Pt 9 935 15314203
  21. [21]Datta K Bartlett K Baer R Spread of Cryptococcus gattii into Pacific Northwest region of the United States Emerg Infect Dis 2009 15 8 1185 91 19757550 PMC2815957
  22. [22]Springer D Chaturvedi V Projecting global occurrence of Cryptococcus gattii Emerg Infect Dis 2010 16 1 14 20 20031037 PMC2874352
  23. [23]Hull CM Heitman J Genetics of Cryptococcus neoformans Annu Rev Genet 2002 36 557 615 12429703
  24. [24]Lin X Hull C Heitman J Sexual reproduction between partners of the same mating type in Cryptococcus neoformans Nature 2005 434 1017 21 15846346
  25. [25]Sukroongreung S Kitiniyom K Nilakul X Pathogenicity of basidiospores of Filobasidiella neoformans var. neoformans Med Mycol 1998 36 6 419 24 10206753
  26. [26]Fraser J Giles S Wenink E Same-sex mating and the origin of the Vancouver Island Cryptococcus gattii outbreak Nature 2005 437 1360 4 16222245
  27. [27]Byrnes E Li W Lewit Y Emergence and pathogenicity of highly virulent Cryptococcus gattii genotypes in the Northwest United States PLoS Pathog 2010 6 4 e1000850 20421942 PMC2858702
  28. [28]Litvintseva A Marra R Nielsen K Evidence of sexual recombination among Cryptococcus neoformans serotype A isolates in sub-Saharan Africa Eukaryot Cell 2003 2 6 1162 8 14665451 PMC326657
  29. [30]Perfect JR Casadevall A Cryptococcosis Infect Dis Clin North Am 2002 16 837 74 12512184
  30. [31]Perfect JR Cryptococcus neoformans and Cryptococcus gattii Bennett JE Dolin R Blaser MJ Mandell, Douglas, and Bennett’s principles and practice of infectious diseases 8th Philadelphia Elsevier Saunders 2015 2934 48
  31. [32]Bratton E El Husseini N Chastain C Comparison and temporal trends of three groups with Cryptococcosis: HIV-infected, solid organ transplant, and HIV-negative/non-transplant PLoS One 2012 7 8 e43582 22937064 PMC3427358
  32. [33]Christianson J Engber W Andes D Primary cutaneous cryptococcosis in immunocompetent and immunocompromised hosts Med Mycol 2003 41 3 177 88 12964709
  33. [34]Goldman D Khine H Abadi J Pediatrics 2001 107 5 E66 11331716
  34. [36]Perfect JR Cryptococcus neoformans: a sugar-coated killer with designer genes FEMS Immunol Med Microbiol 2005 45 395 404 16055314
  35. [37]Sun H Alexander B Lortholary O Unrecognized pretransplant and donor-derived cryptococcal disease in organ transplant recipients Clin Infect Dis 2010 51 9 1062 9 20879857
  36. [38]Krockenberger M Malik R Ngamskulrungroj P Pathogenesis of pulmonary Cryptococcus gattii infection: a rat model Mycopathologia 2010 170 5 315 30 20552280
  37. [39]Santangelo R Zoellner H Sorrell T Role of extracellular phospholipases and mononuclear phagocytes in dissemination of cryptococcosis in a murine model Infect Immun 2004 72 1693 9 15039347 PMC375158
  38. [40]Maruvada R Zhu L Pearce D Cryptococcus neoformans phospholipase B1 activates host cell Rac1 for traversal across the blood-brain barrier Cell Microbiol 2012 14 10 1544 53 22646320 PMC3443264
  39. [41]Ahi M Li S Zheng C Real-time imaging of trapping and urease-dependent transmigration of Cryptococcus neoformans in mouse brain J Clin Invest 2010 120 5 1683 93 20424328 PMC2860939
  40. [42]Charlier C Nielsen K Daou S Evidence of a role for monocytes in dissemination and brain invasion by Cryptococcus neoformans Infect Immun 2009 77 1 120 7 18936186 PMC2612285
  41. [44]Coelho C Bocca A Casadevall A The tools for virulence of Cryptococcus neoformans Adv Appl Microbiol 2014 87 1 41 24581388
  42. [45]Okagaki L Strain A Nielsen J Cryptococcal cell morphology affects host cell interactions and pathogenicity PLoS Pathog 2010 6 e1000953 20585559 PMC2887476
  43. [48]Alvarez M Casadevall A Phagosome extrusion and host-cell survival after Cryptococcus neoformans phagocytosis by macrophages Curr Biol 2006 16 2161 5 17084702
  44. [49]Geunes-Boyer S Beers M Perfect J Surfactant protein D facilitates Cryptococcus neoformans infection Infect Immun 2012 80 7 2444 53 22547543 PMC3416458
  45. [50]Warr W Bates JH Stone A The spectrum of pulmonary cryptococcosis Ann Intern Med 1968 69 1109 16 5725729
  46. [51]Brizendine K Baddley J Pappas P Pulmonary cryptococcosis Semin Respir Crit Care Med 2011 32 6 727 34 22167400
  47. [52]Chen S Korman T Slavin M Antifungal therapy and management of complications of cryptococcosis due to Cryptococcus Gattii Clin Infect Dis 2013 57 4 543 51 23697747
  48. [53]Franco-Paredes C Womack T Bohlmeyer T Management of Cryptococcus gattii meningoencephalitis Lancet Infect Dis 2015 15 348 55 25467646 PMC4481715
  49. [54]Speed B Dunt D Clinical and host differences between infections with the two varieties of Cryptococcus neoformans Clin Infect Dis 1995 21 28 34 7578756
  50. [55]Singh N Gayowski T Wagener MM Clinical spectrum of invasive cryptococcosis in liver transplant recipients receiving tacrolimus Clin Transplant 1997 11 66 70 9067698
  51. [56]Odom A Muir S Lim E Calcineurin is required for virulence of Crytptococcus neoformans EMBO J 2007 16 2576 89 PMC1169869 9184205
  52. [57]Allen R Barter CE Cachou LL Disseminated cryptococcosis after transurethral resection of the prostate Aust N Z J Med 1982 12 296 9 6958242
  53. [58]Larsen RA Bozzette S McCutchan JA Persistent Cryptococcus neoformans infection of the prostate after successful treatment of meningitis. California Collaborative Treatment Group Ann Intern Med 1989 111 125 8 2545124
  54. [59]Staib F Seibold M L’Age M Persistence of Cryptococcus neoformans in seminal fluid and urine under itraconazole treatment. The urogenital tract (prostate) as a niche for Cryptococcus neoformans Mycoses 1990 33 369 73 1965324
  55. [60]Okun E Butler WT Ophthalmologic complications of cryptococcal meningitis Arch Ophthalmol 1964 71 52 7 14066039
  56. [61]Rex JH Larsen RA Dismukes WE Catastrophic visual loss due to Cryptococcus neoformans meningitis Medicine (Baltimore) 1993 72 207 24 8341139
  57. [62]Liu PY Cryptococcal osteomyelitis: case report and review Diagn Microbiol Infect Dis 1998 30 1 33 5 9488829
  58. [63]Albert-Braun S Venema F Bausch J Cryptococcus neoformans peritonitis in a patient with alcoholic cirrhosis: case report and review of the literature Infection 2005 33 282 8 16091901
  59. [64]Shelburne SA Visnegarwala F Darcourt J Incidence and risk factors for immune reconstitution inflammatory syndrome during HAART AIDS 2005 19 4 399 406 15750393
  60. [65]Lortholary O Fontanet A Memain N Incidence and risk factors of immune reconstitution inflammatory syndrome complicating HIV-associated cryptococcosis in France AIDS 2005 19 10 1043 9 15958835
  61. [66]Bicanic T Meintjes G Rebe K Immune reconstitution inflammatory syndrome in HIV-associated cryptococcal meningitis: a prospective study J Acquir Immune Defic Syndr 2009 51 2 130 4 19365271
  62. [67]Sungkanuparph S Filler SG Chetchotisakd P Cryptococcal immune reconstitution inflammatory syndrome after HAART in AIDS patients with cryptococcal meningitis: a prospective multicenter study Clin Infect Dis 2009 49 6 931 4 19681708
  63. [68]Boulware DR Meya DB Bergemann TL Clinical features and serum biomarkers in HIV immune reconstitution inflammatory syndrome after cryptococcal meningitis: a prospective cohort study PLoS Med 2010 7 12 e1000384 21253011 PMC3014618
  64. [69]Haddow LJ Easterbrook PJ Mosam A Defining immune reconstitution inflammatory syndrome: evaluation of expert opinion versus 2 case definitions in a South African cohort Clin Infect Dis 2009 49 9 1424 32 19788360
  65. [70]Shelburne SA 3rd Darcourt J White AC Jr The role of immune reconstitution inflammatory syndrome in AIDS-related Cryptococcus neoformans disease in the era of HAART Clin Infect Dis 2005 40 7 1049 52 15825000
  66. [71]Sungkanuparph S Jongwutiwes U Kiertiburanakul S Timing of cryptococcal immune reconstitution inflammatory syndrome after HAART in patients with AIDS and cryptococcal meningitis J Acquir Immune Defic Syndr 2007 45 5 595 6 17704683
  67. [72]Kambugu A Meya DB Rhein J Outcomes of cryptococcal meningitis in Uganda before and after the availability of HAART Clin Infect Dis 2008 46 11 1694 701 18433339 PMC2593910
  68. [73]Boulware DR Bonham SC Meya DB Paucity of initial cerebrospinal fluid inflammation in cryptococcal meningitis is associated with subsequent immune reconstitution inflammatory syndrome J Infect Dis 2010 202 6 962 70 20677939 PMC2924457
  69. [74]da Cunha Colombo ER Mora DJ Silva-Vergara ML Immune reconstitution inflammatory syndrome (IRIS) associated with Cryptococcus neoformans infection in AIDS patients Mycoses 2011 54 4 e178 82 20337940
  70. [75]Rambeloarisoa J Batisse D Thiebaut JB Intramedullary abscess resulting from disseminated cryptococcosis despite immune restoration in a patient with AIDS J Infect 2002 44 3 185 8 12099747
  71. [76]Skiest DJ Hester LJ Hardy RD Cryptococcal immune reconstitution inflammatory syndrome: report of four cases in three patients and review of the literature J Infect 2005 51 5 e289 97 16321643
  72. [77]Singh N Lortholary O Alexander BD Allograft loss in renal transplant recipients with Cryptococcus neoformans associated immune reconstitution syndrome Transplantation 2005 80 8 1131 3 16278598
  73. [79]Sun HY Singh N Opportunistic infection-associated immune reconstitution syndrome in transplant recipients Clin Infect Dis 2011 53 2 168 76 21690625
  74. [80]Lanternier F Chandesris MO Poiree S Cellulitis revealing a cryptococcosis-related immune reconstitution inflammatory syndrome in a renal allograft recipient Am J Transplant 2007 7 12 2826 8 17927804
  75. [81]Crespo G Cervera C Michelena J Immune reconstitution syndrome after voriconazole treatment for cryptococcal meningitis in a liver transplant recipient Liver Transplant 2008 14 11 1671 4 18975277
  76. [82]Singh N Novel immune regulatory pathways and their role in immune reconstitution syndrome in organ transplant recipients with invasive mycoses Eur J Clin Microbiol Infect Dis 2008 27 6 403 8 18214557 PMC2702776
  77. [83]Sun H Alexander B Huprikar S Predictors of immune reconstitution syndrome in organ transplant recipients with cryptococcosis: implications for the management of immunosuppression Clin Infect Dis 2015 60 1 36 44 25210020 PMC6283360
  78. [84]Ecevit IZ Clancy CJ Scmalfuss IM The poor prognosis of central nervous system cryptococcosis among nonimmunosuppressed patients: a call for better disease recognition and evaluation of adjuncts to antifungal therapy Clin Infect Dis 2006 42 1443 7 16619158
  79. [85]Haddow LJ Colebunders R Meintjes G Cryptococcal immune reconstitution inflammatory syndrome in HIV-1-infected individuals: proposed clinical case definitions Lancet Infect Dis 2010 10 11 791 802 21029993 PMC3026057
  80. [86]Tan DB Yong YK Tan HY Immunological profiles of immune restoration disease presenting as mycobacterial lymphadenitis and cryptococcal meningitis HIV Med 2008 9 5 307 16 18400078
  81. [87]Scriven J Rhein J Hullsiek K Early ART after cryptococcal meningitis is associated with cerebrospinal fluid pleocytosis and macrophage activation in a multisite randomized trial J Infect Dis 2015 212 5 769 78 25651842 PMC4527410
  82. [88]Jarvis J Meintjes G Bicanic T Cerebrospinal fluid cytokine profiles predict risk of early mortality and immune reconstitution inflammatory syndrome in HIV-associated cryptococcal meningitis PLoS Pathog 2014 11 4 e1004754 PMC4390200 25853653
  83. [89]Chang C Omarjee S Lim A Chemokine levels and chemokine receptor expression in the blood and the cerebrospinal fluid of HIV-infected patients with cryptococcal meningitis and cryptococcosis-associated immune reconstitution syndrome J Infect Dis 2013 208 1604 12 23908492 PMC3805241
  84. [90]Trevenzoli M Cattelan AM Rea F Mediastinitis due to cryptococcal infection: a new clinical entity in the HAART era J Infect 2002 45 3 173 9 12387774
  85. [91]Blanche P Gombert B Ginsburg C HIV combination therapy: immune restitution causing cryptococcal lymphadenitis dramatically improved by anti-inflammatory therapy Scand J Infect Dis 1998 30 6 615 6 10225395
  86. [92]Meintjes G Lawn SD Scano F Tuberculosis-associated immune reconstitution inflammatory syndrome: case definitions for use in resource-limited settings Lancet Infect Dis 2008 8 8 516 23 18652998 PMC2804035
  87. [93]Perfect JR Dismukes WE Dromer F Clinical Practice Guide lines for the Management of Cryptococcal Disease: 2010 update by the Infectious Disease Society of America Clin Infect Dis 2010 50 291 322 20047480 PMC5826644
  88. [94]Bicanic T Harrison T Niepieklo A Symptomatic relapse of HIV-associated cryptococcal meningitis after initial fluconazole monotherapy: the role of fluconazole resistance and immune reconstitution Clin Infect Dis 2006 43 8 1069 73 16983622
  89. [96]Meintjes G Wilkinson RJ Morroni C Randomized placebo-controlled trial of prednisone for paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome AIDS 2010 24 15 2381 90 20808204 PMC2940061
  90. [97]Graybill JR Sobel J Saag M Diagnosis and management of increased intracranial pressure in patients with AIDS and cryptococcal meningitis. The NIAID Mycoses Study Group and AIDS Cooperative Treatment Groups Clin Infect Dis 2000 30 1 47 54 10619732
  91. [98]Narayanan S Banerjee C Holt PA Cryptococcal immune reconstitution syndrome during steroid withdrawal treated with hydroxychloroquine Int J Infect Dis 2011 15 1 e70 3 21094071
  92. [99]Sitapati AM Kao CL Cachay ER Treatment of HIV-related inflammatory cerebral cryptococcoma with adalimumab Clin Infect Dis 2010 50 2 e7 10 20001539
  93. [100]Scemla A Gerber S Duquesne A Dramatic improvement of severe cryptococcosis-induced immune reconstitution syndrome with adalimumab in a renal transplant recipient Am J Transplant 2015 15 560 4 25611999
  94. [101]Brunel A Reynes J Tuaillon E Thalidomide for steroid-dependent immune reconstitution inflammatory syndromes during AIDS AIDS 2012 26 16 2110 2 22874513
  95. [102]Biagetti C Nicola M Borderi M Paradoxical immune reconstitution inflammatory syndrome associated with previous Cryptococcus neoformans infection in an HIV-positive patient requiring neurosurgical intervention New Microbiol 2009 32 2 209 12 19579702
  96. [103]Zolopa A Andersen J Powderly W Early HAART reduces AIDS progression/death in individuals with acute opportunistic infections: a multicenter randomized strategy trial PLoS One 2009 4 5 e5575 19440326 PMC2680972
  97. [104]French MA HIV/AIDS: immune reconstitution inflammatory syndrome: a reappraisal Clin Infect Dis 2009 48 1 101 7 19025493
  98. [105]Diamond RD Bennett JE Prognostic factors in cryptococcal meningitis. A study in 111 cases Ann Intern Med 1974 80 176 81 4811791
  99. [106]Antinori S New Insights into HIV/AIDS-Associated Cryptococcosis ISRN AIDS 2013 2013 471363 24052889 PMC3767198
  100. [107]Shibuya K Coulson WF Wollman JS Histopathology of cryptococcosis and other fungal infections in patients with acquired immunodeficiency syndrome Int J Infect Dis 2001 5 78 85 11468102
  101. [108]Sato Y Osabe S Kuno H Rapid diagnosis of cryptococcal meningitis by microscopic examination of centrifuged cerebrospinal fluid sediment J Neurol Sci 1999 164 72 5 10385051
  102. [109]Kanjanavirojkul N Sripa C Puapairoj A Cytologic diagnosis of Cryptococcus neoformans in HIV-positive patients Acta Cytol 1997 41 493 6 9100786
  103. [110]Malabonga VM Basti J Kamholz SL Utility of bronchoscopic sampling techniques for cryptococcal disease in AIDS Chest 1991 99 370 2 1989797
  104. [111]Lee LN Yang PC Kuo SH Diagnosis of pulmonary cryptococcosis by ultrasound guided percutaneous aspiration Thorax 1993 48 75 8 8434359 PMC464253
  105. [112]Tanner DC Weinstein MP Fedorciw B Comparison of commercial kits for detection of cryptococcal antigen J Clin Microbiol 1994 32 1680 4 7929757 PMC263761
  106. [113]Wu TC Koo SY Comparison of three commercial cryptococcal latex kits for detection of cryptococcal antigen J Clin Microbiol 1983 18 1127 30 6643665 PMC272854
  107. [114]Stamm AM Polt SS False-negative cryptococcal antigen test JAMA 1980 244 1359 6997519
  108. [115]Bloomfield N Gordon MA Elmendorf DF Detection of Cryptococcus neoformans antigen in body fluids by latex particle agglutination Proc Soc Exp Biol Med 1963 114 64 7 14076914
  109. [116]Jarvis JN Percival A Bauman S Evaluation of a novel point-of-care cryptococcal antigen test on serum, plasma and urine from patients with HIV-associated cryptococcal meningitis Clin Infect Dis 2011 53 1019 23 21940419 PMC3193830
  110. [117]Lindsley MD Mekha N Baggett HC Evaluation of a newly developed lateral flow immunoassay for the diagnosis of Cryptococcus Clin Infect Dis 2011 53 321 5 21810743 PMC3148258
  111. [118]McMullan BJ Halliday C Sorrell TC Clinical utility of the cryptococcal antigen lateral flow assay in a diagnostic mycology laboratory PLoS One 2012 7 e49451 23166705 PMC3498116
  112. [119]Binnicker MJ Jespersen DJ Bestrom JE Comparison of four assays for the detection of cryptococcal antigen Clin Vaccine Immunol 2012 19 1988 90 23081814 PMC3535868
  113. [120]Hansen J Slechta ES Gates-Hollingsworth MA Large-scale evaluation of the Immuno-Mycologics lateral flow and Enzyme-Linked immunoassays for detection of cryptococcal antigen in serum and cerebrospinal fluid Clin Vaccine Immunol 2013 20 52 5 23114703 PMC3535775
  114. [121]Huang H Fan L Rajbanshi B Evaluation of a new cryptococcal antigen lateral flow immunoassay in serum, cerebrospinal fluid and urine for the diagnosis of cryptococcosis: a meta-analysis and systematic review PLoS One 2015 10 5 e0127117 25974018 PMC4431798
  115. [122]Kabanda T Siedner M Klausner J Point-of-care diagnosis and prognostication of cryptococcal meningitis with the cryptococcal lateral flow assay on cerebrospinal fluid Clin Infect Dis 2014 58 1 113 6 24065327 PMC3864499
  116. [123]Williams D Kiiza T Kwizera R Evaluation of fingerstick cryptococcal antigen lateral flow assay in HIV-infected persons: a diagnostic accuracy study Clin Infect Dis 2015 61 3 464 7 25838287 PMC4503809
  117. [124]Jarvis JN Harrison TS Lawn SD Cost effectiveness of cryptococcal antigen screening as a strategy to prevent cryptococcal meningitis in South Africa PLoS One 2013 8 e69288 23894442 PMC3716603
  118. [125]Bindschadler DD Bennett JE Serology of human cryptococcosis Ann Intern Med 1968 69 45 52 4872700
  119. [126]Saag MS Powderly WG Cloud GA Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis. The NIAID Mycoses Study Group and the AIDS Clinical Trials Group N Engl J Med 1992 326 8 3 89 1727236
  120. [127]Powderly WG Cloud GA Dismukes WE Measurement of cryptococcal antigen in serum and cerebrospinal fluid: value in the management of AIDS-associated cryptococcal meningitis Clin Infect Dis 1994 18 789 92 8075272
  121. [128]Bicanic T Meintjes G Wood R Fungal burden, early fungicidal activity, and outcome in cryptococcal meningitis in antiretroviral-naive or antiretroviral-experienced patients treated with amphotericin B or fluconazole Clin Infect Dis 2007 45 1 76 80 17554704
  122. [130]Perfect J Bicanic T Cryptococcosis diagnosis and treatment: what do we know now Fungal Genet Biol 2015 78 49 54 25312862 PMC4395512
  123. [131]Leenders AC Reiss P Portegies P Liposomal amphotericin B (AmBisome) compared with amphotericin B both followed by oral fluconazole in the treatment of AIDS-associated cryptococcal meningitis AIDS 1997 11 1463 71 9342068
  124. [132]Hamill RJ Sobel JD El-Sadr W Comparison of 2 doses of liposomal amphotericin B and conventional amphotericin B deoxycholate for treatment of AIDS-associated acute cryptococcal meningitis: a randomized, double-blind clinical trial of efficacy and safety Clin Infect Dis 2010 51 2 225 32 20536366
  125. [133]van der Horst CM Saag MS Cloud GA Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Mycoses Study Group and AIDS Clinical Trials Group N Engl J Med 1997 337 15 21 9203426
  126. [134]Dismukes WE Cloud G Gallis HA Treatment of cryptococcal meningitis with combination amphotericin B and flucytosine for four as compared with six weeks N Engl J Med 1987 317 334 41 3299095
  127. [135]Day JN Chau T Wolbers M Combination antifungal therapy for cryptococcal meningitis N Engl J Med 2013 368 1291 302 23550668 PMC3978204
  128. [136]Brouwer AE Rajanuwong A Chieraku W Combination antifungal therapies for HIV-associated cryptococcal meningitis: a randomised trial Lancet 2004 363 1764 7 15172774
  129. [137]Dromer F Bernede-Bauduin C Guillemot D Major role for amphotericin-flucytosine combination in severe cryptococcosis PLoS One 2008 3 8 e2870 18682846 PMC2483933
  130. [138]O’Connor L Livermore J Sharp A Pharmacodynamics of liposomal amphotericin B and flucytosine for cryptococcal meningoencephalitis: safe and effective regimens for immunocompromised patients J Infect Dis 2013 208 351 61 23599314 PMC3685229
  131. [139]Bratton E El Husseini N Chastain C Approaches to antifungal therapies and their effectiveness among patients with cryptococcosis Antimicrob Agents Chemother 2013 57 6 2485 95 23478968 PMC3716133
  132. [140]Robinson PA Bauer M Leal MAE Early mycological treatment failure in AIDS-associated cryptococcal meningitis Clin Infect Dis 1999 28 82 92 10028076
  133. [141]Dromer F Mathoulin-Pelissier S Launay O Determinants of disease presentation and outcome during cryptococcosis: The Crypto A/D Study PLoS Med 2007 4 e21 17284154 PMC1808080
  134. [143]Pappas PG Chetchotisakd P Larsen RA A phase II randomized trial of amphotericin B alone or combined with fluconazole in the treatment of HIV-associated cryptococcal meningitis Clin Infect Dis 2009 48 1775 83 19441980
  135. [144]Loyse A Wilson D Meintjes G Comparison of the early fungicidal activity of high-dose fluconazole, voriconazole, and flucytosine as second-line drugs given in combination with amphotericin B for the treatment of HIV-associated cryptococcal meningitis Clin Infect Dis 2012 54 121 8 22052885
  136. [145]Bahr N Rolfes M Musubire A Standardized electrolyte supplementation and fluid management improves survival during amphotericin therapy for cryptococcal meningitis in resource-limited settings Open Forum Infect Dis 2014 1 2 ofu070 25734140 PMC4281785
  137. [146]Muzoora C Kabanda T Ortu G Short course amphotericin B with high dose fluconazole for HIV-associated cryptococcal meningitis J Infect 2012 64 76 81 22079502
  138. [148]Nussbaum JC Jackson A Namarika D Combination flucytosine and high-dose fluconazole compared with fluconazole monotherapy for the treatment of cryptococcal meningitis: a randomized trial in Malawi Clin Infect Dis 2010 50 338 44 20038244 PMC2805957
  139. [149]Bozette SA Larsen RA Chiu J A placebo-controlled trial of maintenance therapy with fluconazole after treatment for cryptococcal meningitis in the Acquired Immunodeficiency Syndrome N Engl J Med 1991 324 580 4 1992319
  140. [150]Vibhagool A Sungkanuparph S Mootsikapun P Discontinuation of secondary prophylaxis for cryptococcal meningitis in human immunodeficiency virus-infected patients treated with HAART: a prospective, multicenter, randomized study Clin Infect Dis 2003 36 1329 31 12746781
  141. [151]Mussini C Pezzotti P Miro JM Discontinuation of maintenance therapy for cryptococcal meningitis in patients with AIDS treated with HAART: an international observational study Clin Infect Dis 2004 38 565 71 14765351
  142. [152]Denning DW Tucker RM Hanson LH Itraconazole therapy for cryptococcal meningitis and cryptococcosis Arch Intern Med 1989 149 2301 8 2552949
  143. [153]Saag MS Cloud GA Graybill JR A comparison of itraconazole versus fluconazole as maintenance therapy for AIDS-associated cryptococcal meningitis. National Institute of Allergy and Infectious Diseases Mycoses Study Group Clin Infect Dis 1999 28 291 6 10064246
  144. [154]Perfect JR Marr KA Walsh TJ Voriconazole treatment for less-common, emerging or refractory fungal infections Clin Infect Dis 2003 36 9 1122 31 12715306
  145. [155]Pitisuttithum P Negroni R Graybill JR Activity of posaconazole in the treatment of central nervous system fungal infections J Antimicrob Chemother 2005 56 745 55 16135526
  146. [156]Bisson G Molefi M Bellamy S Early versus delayed antiretroviral therapy and cerebrospinal fluid fungal clearance in adults with HIV and cryptococcal meningitis Clin Infect Dis 2013 56 8 1165 73 23362285
  147. [157]Njei B Kongnyuy EJ Kumar S Optimal timing for HAART initiation in patients with HIV infection and concurrent cryptococcal meningitis Cochrane Database Syst Rev 2013 2 CD009012 23450595
  148. [158]Makadzange AT Ndhlovu CE Takarinda K Early versus delayed initiation of HAART for concurrent HIV infection and cryptococcal meningitis in sub-Saharan Africa Clin Infect Dis 2010 50 11 1532 8 20415574
  149. [159]Abdool Karim S Naidoo K Grobler A Integration of antiretroviral therapy with tuberculosis treatment N Engl J Med 2011 365 16 1492 22010915 PMC3233684
  150. [160]Blanc F Sok T Laureillard D Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis N Engl J Med 2011 365 16 1471 22010913 PMC4879711
  151. [161]Boulware D Meya D Muzoora C Timing of antiretroviral therapy after cryptococcal meningitis N Engl J Med 2014 370 2487 98 24963568 PMC4127879
  152. [162]Singh N Lortholary O Alexander BD Antifungal management practices and evolution of infection in organ transplant recipients with Cryptococcus neoformans infection Transplantation 2005 80 1033 9 16278582
  153. [163]Singh N Lortholary O Alexander BD An immune reconstitution syndrome-like illness associated with Cryptococcus neoformans infection in organ transplant recipients Clin Infect Dis 2005 40 1756 61 15909263
  154. [164]Bennett JE Dismukes WE Duma RJ A comparison of amphotericin B alone and combined with flucytosine in the treatment of cryptococcal meningitis N Engl J Med 1970 301 3 126 31 449951
  155. [165]Denning DW Armstrong RW Lewis BH Elevated cerebrospinal fluid pressures in patients with cryptococcal meningitis and acquired immunodeficiency syndrome Am J Med 1991 91 267 72 1892147
  156. [166]Rolfes M Hullsiek K Rhein J The effect of therapeutic lumbar punctures on acute mortality from cryptococcal meningitis Clin Infect Dis 2014 59 11 1607 14 25057102 PMC4441057
  157. [167]Newton PN Thaile H Tip NQ A randomized, double-blind, placebo-controlled trial of acetazolamide for the treatment of elevated intracranial pressure in cryptococcal meningitis Clin Infect Dis 2002 35 769 72 12203177
  158. [168]Park MK Hospenthal DR Bennett JE Treatment of hydrocephalus secondary to cryptococcal meningitis by use of shunting Clin Infect Dis 1999 28 629 33 10194090
  159. [169]Velez JD Allendorfer R Luther M Correlation of in vitro azole susceptibility testing with in vivo response in a murine model of cryptococcal meningitis J Infect Dis 1993 168 508 10 8335995
  160. [170]Aller AI Martin-Mazuelos E Lozano F Correlation of fluconazole MICs with clinical outcome in cryptococcal infection Antimicrob Agents Chemother 2000 44 1544 8 10817706 PMC89910
  161. [171]Smith R Mba-Jonas A Tourdjman M Treatment and outcomes among patients with Cryptococcus gattii infections in the United States Pacific Northwest PLoS One 2014 9 2 e88875 24586423 PMC3929541
  162. [172]Nightingale SD Cal SX Peterson DM Primary prophylaxis with fluconazole against systemic fungal infections in HIV-positive patients AIDS 1992 6 191 4 1348417
  163. [173]Chetchotisakd P Sungkanuparph S Thinkhamrop B A multicentre, randomized, double-blind, placebo-controlled trial of primary cryptococcal meningitis prophylaxis in HIV-infected patients with severe immune deficiency HIV Med 2004 5 3 140 3 15139978
  164. [174]Chang L Phipps W Kennedy G Antifungal interventions for the primary prevention of cryptococcal disease in adults with HIV Cochrane Database Syst Rev 2005 3 CD004773 16034947
  165. [175]French N Gray K Watera C Cryptococcal infection in a cohort of HIV-1 infected Ugandan adults AIDS 2002 16 1031 8 11953469
  166. [176]McKenney J Bauman S Neary B Prevalence, correlates and outcomes of cryptococcal antigen positivity among patients with AIDS, United States, 1986–2012 Clin Infect Dis 2015 60 6 959 65 25422390 PMC4357818
  167. [177]Jarvis JN Lawn SD Vogt M Screening for cryptococcal antigenemia in patients accessing an antiretroviral treatment program in South Africa Clin Infect Dis 2009 48 856 62 19222372 PMC2875173
  168. [178]Meya D Manabe Y Castelnuovo B Cost-effectiveness of serum cryptococcal antigen screening to prevent deaths among HIV-infected persons with a CD4+ cell count of < 100 cells/μL who start HIV therapy in resource-limited settings Clin Infect Dis 2010 51 4 448 55 20597693 PMC2946373
  169. [179]Kaplan J Vallabhaneni S Smith R Cryptococcal antigen screening and early antifungal treatment to prevent cryptococcal meningitis: a review of the literature J Acquir Immune Defic Syndr 2015 68 S331 9 25768872
  170. [180]Smith R Nguyen T Ha H Prevalence of cryptococcal antigenemia and cost-effectiveness of a cryptococcal antigen screening program – Vietnam PLoS One 2013 8 4 e62213 23626792 PMC3633872
  171. [181]World Health Organization Rapid advice: diagnosis, prevention and management of Cryptococcal disease in HIV-infected adults, adolescents and children Geneva (Switzerland) World Health Organization 2011 26110194
  172. [182]Rajasinham R Boulware D Reconsidering cryptococcal antigen screening in the US among persons with CD4 < 100 cells/mcl Clin Infect Dis 2012 55 1742 4 22918997 PMC3501329
  173. [183]Singh N Dromer F Perfect JR Cryptococcosis in solid organ transplant recipients: current state of the science Clin Infect Dis 2008 47 1321 7 18840080 PMC2696098
  174. [184]Devi SJ Scheerson R Egan W Cryptococcus neoformans serotype A glucuronoxylomannan protein conjugate vaccines: synthesis, characterization, and immunogenicity Infect Immun 1991 59 3700 7 1716613 PMC258941
  175. [185]Mukherjee J Zuckier LS Scharff MD Therapeutic efficacy of monoclonal antibodies to Cryptococcus neoformans glucuronoxylomannan alone and in combination with amphotericin B Antimicrob Agents Chemother 1994 38 580 7 8203858 PMC284501
  176. [186]Wormley F Perfect J Steele C Protection against cryptococcosis by using a murine gamma interferon-producing Cryptococcus neoformans strain Infect Immun 2007 75 1453 63 17210668 PMC1828544
  177. [187]Jarvis J Meintjes G Rebe K Adjunctive interferon-g immunotherapy for the treatment of HIV-associated cryptococcal meningitis: a randomized controlled trial AIDS 2012 26 9 1105 13 22421244 PMC3640254
  178. [189]Isiodras S Samonis G Boumpas D Fungal infections complicating tumor necrosis factora blockade therapy Mayo Clin Proc 2008 83 2 181 94 18241628
  179. [191]Singh N Perfect JR Immune reconstitution syndrome associated with opportunistic mycoses Lancet Infect Dis 2007 7 6 395 401 17521592

Cited by

Sorted by citations

Authors
Maziarz, E. K., & Perfect, J. R.
Affiliations
Duke University (US)
Corresponding author
Maziarz, Eileen K.
ORCID
Venue
Infectious Disease Clinics of North America
Publisher
Elsevier BV
Published
2016-03
Volume
30
Issue
1
Pages
179-206
ISSN
0891-5520 (ISSN-L)
DOI
10.1016/j.idc.2015.10.006
PMC
PMC5808417
OpenAlex
W4210985946
Cited by
698
References
11
Citations by year
2026: 39 · 2025: 79 · 2024: 96 · 2023: 97 · 2022: 96 · 2021: 96 · 2020: 88 · 2019: 43 · 2018: 26 · 2017: 27 · 2016: 10
FWCI
4.78
Type
journal article
Language
en
Open access
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • Infectious Disease Clinics of North America (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
Funders
National Institute of Allergy and Infectious Diseases (R01AI093257)
Topics
  • Health Sciences › Medicine › Epidemiology › Fungal Infections and Studies
  • Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
  • Life Sciences › Immunology and Microbiology › Parasitology › Parasitic Infections and Diagnostics
Keywords
cryptococcosis, Cryptococcus, encapsulated yeast, invasive fungal infections, opportunistic fungal infection, immunocompromised patients, pathobiology, environmental adaptation, geographic spread, point-of-care diagnosis, disease burden, screening method, preemptive therapy
MeSH terms
Antifungal Agents, Cryptococcosis, Cryptococcus, Humans

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review